Fig. 1

SLCO4A1-AS1 is overexpressed in human CRC. a Heatmap of differentially expressed long noncoding RNAs in CRC tissues and adjacent non-tumor tissues according to an online microarray dataset (GSE104836). b The copy number amplifications (CAN) of SLCO4A1-AS1 were determined according to TCGA database. c The CNA of SLCO4A1-AS1 was measured by qRT-PCR in 50 CRC samples. DNAs were extracted from samples and specific primers targeting SLCO4A1-AS1 DNA were used. ACTB DNA was used for loading control. d SLCO4A1-AS1 expression was determined by qRT-PCR in CRC samples (n = 50) and adjacent normal tissues (n = 15). e SLCO4A1-AS1 expression was examined by qRT-PCR in 15 pairs of CRC samples and adjacent normal tissues. f The expression of SLCO4A1-AS1 was determined by in situ hybridization in pairs of CRC samples and adjacent normal tissues (#9 and #13). Scale bar, 50 μm. g The expression levels of SLCO4A1-AS1 were determined by qRT-PCR in human normal colorectal mucosa cell FHC and CRC cell lines (HCT116, HCT8, HT29, SW480, LOVO and SW620). h 50 CRC samples were divided into four groups based on clinical stages (TNMs). And the expression of SLCO4A1-AS1 was measured in each group by qRT-PCR. i The effect of SLCO4A1-AS1 expression on clinical prognosis was determined by Kaplan–Meier survival analysis. Median value was the cutoff threshold of Kaplan–Meier survival analysis. j Prediction of CRC based on SLCO4A1-AS1 expression was analyzed by ROC curve using adjacent normal tissues as control. *p < 0.05, **p < 0.01 and ***p < 0.01